In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling

[Display omitted] •An in vitro- and in silico-based integrated risk assessment approach is described.•This approach is used to derive human equivalent doses for BPA, BPS, BPF, and BPAF.•Combined risks of BPA and its analogues for different populations are assessed.•Combined risks for toddlers and ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hazardous materials 2020-11, Vol.399, p.122856-122856, Article 122856
Hauptverfasser: Lin, Yi-Jun, Lin, Zhoumeng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 122856
container_issue
container_start_page 122856
container_title Journal of hazardous materials
container_volume 399
creator Lin, Yi-Jun
Lin, Zhoumeng
description [Display omitted] •An in vitro- and in silico-based integrated risk assessment approach is described.•This approach is used to derive human equivalent doses for BPA, BPS, BPF, and BPAF.•Combined risks of BPA and its analogues for different populations are assessed.•Combined risks for toddlers and adults with high dietary exposure may be of concern.•This study shows it is feasible to use in vitro assays for human health risk assessment. Combined risk assessment of endocrine effects of bisphenol A (BPA) and its analogues, such as bisphenols S, F, and AF (BPS, BPF, and BPAF), is challenging due to lack of related common toxicity metrics. This study conducted a population-based in vitro-to-in vivo extrapolation using physiologically based pharmacokinetic (PBPK) models coupled with Monte Carlo simulations to convert ToxCast in vitro estrogen receptor (ER) assays to human equivalent doses (HEDs). The ER pathway-based HEDs were compared with HEDs from animal studies and used to assess the combined risks for different populations across different countries/regions in a probabilistic manner. The estimated ER pathway-based HEDs for the four bisphenols (BPs) matched the animal-derived HEDs. The HEDs for the ER gene transcription (the common biological process target among BPs) were 0.40 (2.5th–97.5th percentiles: 0.06–5.42), 4.43 (0.69–53.84), 3.30 (0.51–626.57), and 1.12 (0.16–9.73) mg/kg/day for BPA, BPS, BPF, and BPAF, respectively. Results suggest a potentially moderate concern for combined risks of activating the ER pathway for toddlers and adults with high dietary exposures. This study presents in vitro-based credible HEDs for the four BPs and represents an advancement in the application of in vitro–in silico-based alternative approaches in human health risk assessment.
doi_str_mv 10.1016/j.jhazmat.2020.122856
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443880759</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304389420308451</els_id><sourcerecordid>2443880759</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-759173993332c18e18c79ca0097cd6af89f3e36131aec4b19a05504330d4d0513</originalsourceid><addsrcrecordid>eNqFkk1z0zAQhg0DQ0PLT4DRMT04SJY_T0zJFMjQGXoovXrW8iZWakuuVg4Nvx6FBDhykmb17j67qzeK3gq-EFzk77eLbQc_B_CLhCchliRllj-PZqIsZCylzF9EMy55GsuySs-i10RbzrkosvRVdCaTShZ5lc2eXawM22nvbKwNI91rZeMGCFs2OttAEyLktWJO0wMDIiQa0Hhm10zZodEmKPFptDQ5ZN6yRtPYobE9u2JgWqY9hRN6u5mQWLNn2njcOPDabNidfVoCedbpTRf7ztlp042TD5pjTwcg7In90L77FwyU3_edDWTvYLR9KGcNm6_uV_fXl-EJ2NjtSduA1Qr6fs9OM3XgBlD2IfR9mGp--_H26yUbbIt9aOgiermGnvDN6TyPvn-6vlt-iW--fV4tr25iJfPMx0VWiUJWVdhyokSJolRFpYDzqlBtDuuyWkuUuZACUKWNqIBnGU-l5G3a8kzI82h-rBt2_Bj24utBk8K-B4N2ojpJU1mWPHCCNDtKlbNEDtf16PQAbl8LXh-MUG_rkxHqgxHqoxFC3rsTYmoGbP9m_fn5IPhwFGAYdKfR1aQ0GoWtdqh83Vr9H8QvJzvMXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443880759</pqid></control><display><type>article</type><title>In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lin, Yi-Jun ; Lin, Zhoumeng</creator><creatorcontrib>Lin, Yi-Jun ; Lin, Zhoumeng</creatorcontrib><description>[Display omitted] •An in vitro- and in silico-based integrated risk assessment approach is described.•This approach is used to derive human equivalent doses for BPA, BPS, BPF, and BPAF.•Combined risks of BPA and its analogues for different populations are assessed.•Combined risks for toddlers and adults with high dietary exposure may be of concern.•This study shows it is feasible to use in vitro assays for human health risk assessment. Combined risk assessment of endocrine effects of bisphenol A (BPA) and its analogues, such as bisphenols S, F, and AF (BPS, BPF, and BPAF), is challenging due to lack of related common toxicity metrics. This study conducted a population-based in vitro-to-in vivo extrapolation using physiologically based pharmacokinetic (PBPK) models coupled with Monte Carlo simulations to convert ToxCast in vitro estrogen receptor (ER) assays to human equivalent doses (HEDs). The ER pathway-based HEDs were compared with HEDs from animal studies and used to assess the combined risks for different populations across different countries/regions in a probabilistic manner. The estimated ER pathway-based HEDs for the four bisphenols (BPs) matched the animal-derived HEDs. The HEDs for the ER gene transcription (the common biological process target among BPs) were 0.40 (2.5th–97.5th percentiles: 0.06–5.42), 4.43 (0.69–53.84), 3.30 (0.51–626.57), and 1.12 (0.16–9.73) mg/kg/day for BPA, BPS, BPF, and BPAF, respectively. Results suggest a potentially moderate concern for combined risks of activating the ER pathway for toddlers and adults with high dietary exposures. This study presents in vitro-based credible HEDs for the four BPs and represents an advancement in the application of in vitro–in silico-based alternative approaches in human health risk assessment.</description><identifier>ISSN: 0304-3894</identifier><identifier>EISSN: 1873-3336</identifier><identifier>DOI: 10.1016/j.jhazmat.2020.122856</identifier><identifier>PMID: 32937695</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Animals ; Benzhydryl Compounds - toxicity ; Bisphenol AF ; Bisphenol F ; Bisphenol S ; Combined risk assessment ; Computer Simulation ; High-Throughput Screening Assays ; Humans ; In vitro to in vivo extrapolation (IVIVE) ; Phenols ; Risk Assessment</subject><ispartof>Journal of hazardous materials, 2020-11, Vol.399, p.122856-122856, Article 122856</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-759173993332c18e18c79ca0097cd6af89f3e36131aec4b19a05504330d4d0513</citedby><cites>FETCH-LOGICAL-c365t-759173993332c18e18c79ca0097cd6af89f3e36131aec4b19a05504330d4d0513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304389420308451$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32937695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Yi-Jun</creatorcontrib><creatorcontrib>Lin, Zhoumeng</creatorcontrib><title>In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling</title><title>Journal of hazardous materials</title><addtitle>J Hazard Mater</addtitle><description>[Display omitted] •An in vitro- and in silico-based integrated risk assessment approach is described.•This approach is used to derive human equivalent doses for BPA, BPS, BPF, and BPAF.•Combined risks of BPA and its analogues for different populations are assessed.•Combined risks for toddlers and adults with high dietary exposure may be of concern.•This study shows it is feasible to use in vitro assays for human health risk assessment. Combined risk assessment of endocrine effects of bisphenol A (BPA) and its analogues, such as bisphenols S, F, and AF (BPS, BPF, and BPAF), is challenging due to lack of related common toxicity metrics. This study conducted a population-based in vitro-to-in vivo extrapolation using physiologically based pharmacokinetic (PBPK) models coupled with Monte Carlo simulations to convert ToxCast in vitro estrogen receptor (ER) assays to human equivalent doses (HEDs). The ER pathway-based HEDs were compared with HEDs from animal studies and used to assess the combined risks for different populations across different countries/regions in a probabilistic manner. The estimated ER pathway-based HEDs for the four bisphenols (BPs) matched the animal-derived HEDs. The HEDs for the ER gene transcription (the common biological process target among BPs) were 0.40 (2.5th–97.5th percentiles: 0.06–5.42), 4.43 (0.69–53.84), 3.30 (0.51–626.57), and 1.12 (0.16–9.73) mg/kg/day for BPA, BPS, BPF, and BPAF, respectively. Results suggest a potentially moderate concern for combined risks of activating the ER pathway for toddlers and adults with high dietary exposures. This study presents in vitro-based credible HEDs for the four BPs and represents an advancement in the application of in vitro–in silico-based alternative approaches in human health risk assessment.</description><subject>Adult</subject><subject>Animals</subject><subject>Benzhydryl Compounds - toxicity</subject><subject>Bisphenol AF</subject><subject>Bisphenol F</subject><subject>Bisphenol S</subject><subject>Combined risk assessment</subject><subject>Computer Simulation</subject><subject>High-Throughput Screening Assays</subject><subject>Humans</subject><subject>In vitro to in vivo extrapolation (IVIVE)</subject><subject>Phenols</subject><subject>Risk Assessment</subject><issn>0304-3894</issn><issn>1873-3336</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1z0zAQhg0DQ0PLT4DRMT04SJY_T0zJFMjQGXoovXrW8iZWakuuVg4Nvx6FBDhykmb17j67qzeK3gq-EFzk77eLbQc_B_CLhCchliRllj-PZqIsZCylzF9EMy55GsuySs-i10RbzrkosvRVdCaTShZ5lc2eXawM22nvbKwNI91rZeMGCFs2OttAEyLktWJO0wMDIiQa0Hhm10zZodEmKPFptDQ5ZN6yRtPYobE9u2JgWqY9hRN6u5mQWLNn2njcOPDabNidfVoCedbpTRf7ztlp042TD5pjTwcg7In90L77FwyU3_edDWTvYLR9KGcNm6_uV_fXl-EJ2NjtSduA1Qr6fs9OM3XgBlD2IfR9mGp--_H26yUbbIt9aOgiermGnvDN6TyPvn-6vlt-iW--fV4tr25iJfPMx0VWiUJWVdhyokSJolRFpYDzqlBtDuuyWkuUuZACUKWNqIBnGU-l5G3a8kzI82h-rBt2_Bj24utBk8K-B4N2ojpJU1mWPHCCNDtKlbNEDtf16PQAbl8LXh-MUG_rkxHqgxHqoxFC3rsTYmoGbP9m_fn5IPhwFGAYdKfR1aQ0GoWtdqh83Vr9H8QvJzvMXQ</recordid><startdate>20201115</startdate><enddate>20201115</enddate><creator>Lin, Yi-Jun</creator><creator>Lin, Zhoumeng</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201115</creationdate><title>In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling</title><author>Lin, Yi-Jun ; Lin, Zhoumeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-759173993332c18e18c79ca0097cd6af89f3e36131aec4b19a05504330d4d0513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Benzhydryl Compounds - toxicity</topic><topic>Bisphenol AF</topic><topic>Bisphenol F</topic><topic>Bisphenol S</topic><topic>Combined risk assessment</topic><topic>Computer Simulation</topic><topic>High-Throughput Screening Assays</topic><topic>Humans</topic><topic>In vitro to in vivo extrapolation (IVIVE)</topic><topic>Phenols</topic><topic>Risk Assessment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Yi-Jun</creatorcontrib><creatorcontrib>Lin, Zhoumeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hazardous materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Yi-Jun</au><au>Lin, Zhoumeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling</atitle><jtitle>Journal of hazardous materials</jtitle><addtitle>J Hazard Mater</addtitle><date>2020-11-15</date><risdate>2020</risdate><volume>399</volume><spage>122856</spage><epage>122856</epage><pages>122856-122856</pages><artnum>122856</artnum><issn>0304-3894</issn><eissn>1873-3336</eissn><abstract>[Display omitted] •An in vitro- and in silico-based integrated risk assessment approach is described.•This approach is used to derive human equivalent doses for BPA, BPS, BPF, and BPAF.•Combined risks of BPA and its analogues for different populations are assessed.•Combined risks for toddlers and adults with high dietary exposure may be of concern.•This study shows it is feasible to use in vitro assays for human health risk assessment. Combined risk assessment of endocrine effects of bisphenol A (BPA) and its analogues, such as bisphenols S, F, and AF (BPS, BPF, and BPAF), is challenging due to lack of related common toxicity metrics. This study conducted a population-based in vitro-to-in vivo extrapolation using physiologically based pharmacokinetic (PBPK) models coupled with Monte Carlo simulations to convert ToxCast in vitro estrogen receptor (ER) assays to human equivalent doses (HEDs). The ER pathway-based HEDs were compared with HEDs from animal studies and used to assess the combined risks for different populations across different countries/regions in a probabilistic manner. The estimated ER pathway-based HEDs for the four bisphenols (BPs) matched the animal-derived HEDs. The HEDs for the ER gene transcription (the common biological process target among BPs) were 0.40 (2.5th–97.5th percentiles: 0.06–5.42), 4.43 (0.69–53.84), 3.30 (0.51–626.57), and 1.12 (0.16–9.73) mg/kg/day for BPA, BPS, BPF, and BPAF, respectively. Results suggest a potentially moderate concern for combined risks of activating the ER pathway for toddlers and adults with high dietary exposures. This study presents in vitro-based credible HEDs for the four BPs and represents an advancement in the application of in vitro–in silico-based alternative approaches in human health risk assessment.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32937695</pmid><doi>10.1016/j.jhazmat.2020.122856</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0304-3894
ispartof Journal of hazardous materials, 2020-11, Vol.399, p.122856-122856, Article 122856
issn 0304-3894
1873-3336
language eng
recordid cdi_proquest_miscellaneous_2443880759
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Animals
Benzhydryl Compounds - toxicity
Bisphenol AF
Bisphenol F
Bisphenol S
Combined risk assessment
Computer Simulation
High-Throughput Screening Assays
Humans
In vitro to in vivo extrapolation (IVIVE)
Phenols
Risk Assessment
title In vitro-in silico-based probabilistic risk assessment of combined exposure to bisphenol A and its analogues by integrating ToxCast high-throughput in vitro assays with in vitro to in vivo extrapolation (IVIVE) via physiologically based pharmacokinetic (PBPK) modeling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro-in%20silico-based%20probabilistic%20risk%20assessment%20of%20combined%20exposure%20to%20bisphenol%20A%20and%20its%20analogues%20by%20integrating%20ToxCast%20high-throughput%20in%20vitro%20assays%20with%20in%20vitro%20to%20in%20vivo%20extrapolation%20(IVIVE)%20via%20physiologically%20based%20pharmacokinetic%20(PBPK)%20modeling&rft.jtitle=Journal%20of%20hazardous%20materials&rft.au=Lin,%20Yi-Jun&rft.date=2020-11-15&rft.volume=399&rft.spage=122856&rft.epage=122856&rft.pages=122856-122856&rft.artnum=122856&rft.issn=0304-3894&rft.eissn=1873-3336&rft_id=info:doi/10.1016/j.jhazmat.2020.122856&rft_dat=%3Cproquest_cross%3E2443880759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443880759&rft_id=info:pmid/32937695&rft_els_id=S0304389420308451&rfr_iscdi=true